Posted by Michael Wonder on 15 Mar 2022
BeiGene and Medison announce approval and national reimbursement in Israel for Brukinsa (zanubrutinib) for the treatment of Waldenström's macroglobulinaemia
15 March 2022 - Second regulatory approval for Brukinsa in Israel. ...
Read more →